All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-09-24T13:39:36.000Z

Bimekizumab receives FDA approval for the treatment of psoriatic arthritis

Sep 24, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in psoriatic arthritis.

On September 23, 2024, the U.S Food and Drug Administration (FDA) approved bimekizumab, an interleukin (IL)-17 inhibitor that dually inhibits IL-17A and IL-17F, for the treatment of active psoriatic arthritis (PsA) in adults, in addition to active non-radiographic axial spondylarthritis and active ankylosing spondylarthritis.1 Bimekizumab was previously approved for the treatment of moderate-to-severe plaque psoriasis.1  

The approval in PsA follows positive results from the phase III multicenter, randomized, placebo-controlled BE OPTIMAL and BE COMPLETE trials, which met the primary endpoint of 50% improvement in American College of Rheumatology response (ACR50) at Week 16.1 Responses were sustained to Week 52 in these trials and the open-label extension.1 

This expanded indication makes bimekizumab a promising treatment option in patients with psoriasis at risk of PsA or in those with concurrent PsA.  

  1. PR Newswire. UCB announces U.S. FDA approvals for BIMZELX® (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. https://www.prnewswire.com/news-releases/ucb-announces-us-fda-approvals-for-bimzelx-bimekizumab-bkzx-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis-302255482.html. Published Sep 23, 2024. Accessed Sep 25, 2024. 

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
2 votes - 38 days left ...

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox